

20-22 November 2018

# INTERNATIONAL CONFERENCE ON HEMATOLOGICAL DISEASES




2018

[View all speakers](#)

## Speakers

### **Professor Martin H. Steinberg, MD** **Boston University School of Medicine, Boston, USA**



Graduated from Tufts University School of Medicine, Boston, Massachusetts in 1962 followed by a medical internship at Bellevue Hospital, New York. Subsequently, Professor Steinberg held a number of positions in prestigious institutions, including New England Medical Center Hospitals and Tufts University School of Medicine. In 1970, he became Assistant Professor of Medicine at the University of Mississippi School of Medicine and in 1973, he was appointed as the Associate Chief of Staff for Research and Development at VA Medical Center, Jackson, Mississippi and Assistant Dean for Coordination of Research at the University of Mississippi School of Medicine, positions he held until 2000.

In 2000, he became a Professor of Medicine and a Professor of Pediatrics at Boston University School of Medicine and the Director, Center of Excellence in Sickle Cell Disease at Boston Medical Center, and following these appointments, he became a Professor of Pathology and Laboratory Medicine. Professor Steinberg is also a consultant to the Food and Drug Administration (FDA) and the National Institutes of Health (NIH), which is one of the world's foremost medical research centers. Professor Steinberg's clinical, research expertise lies in the clinical aspects of hemoglobinopathies and genetics of hemoglobin disorders, and he has published over 300 papers including articles in New England Journal of Medicine, Nature and Science.

## **Professor Hatem Salem, MD**



Professor Salem received his doctorate degree from Monash University, Australia in 1984 and is currently a Professor of Medicine at Monash University and the Director of Clinical Hematology, Alfred Hospital, Melbourne, Australia. His interest lies in blood disorders, in particular thrombosis and hemostasis and he has been the recipient of many awards and grants throughout his career. In 2005, as a result of his vision and ability to develop leading clinical and research programs, he was awarded the Health Minister's Award for Outstanding Individual Achievement by the Victorian Government's Public Healthcare Award. In 2010, Professor Salem was awarded the Member of the Order of Australia for service to medicine in the field of hematology as a clinician, educator and researcher. One of Professor Salem's greatest achievements is the establishment of the Australian Centre for Blood Diseases, a state-of-the-art facility that is a recognized leader in blood disease research and education in the diagnosis and treatment of blood conditions. He was the center's director until the end of 2012. Professor Salem has published over 140 papers including articles in *Blood*, *British Journal of Surgery* and *Nature Medicine*.



## **Professor Stephen M. Jane , MD**

Obtained his medical degree from Monash University, Melbourne, Australia. He entered the physician-training program at the Alfred Hospital and completed his PhD under Professor Hatem Salem, who was the Director of the Australian Centre for Blood Diseases until 2012. Professor Jane subsequently spent five years in the US, the first three years as a postdoctoral fellow at the National Institutes of Health (NIH), one of the world's most renowned medical research centers followed by two years as a faculty member of St Jude Children's Research Hospital in Memphis, Tennessee. Following this, he returned to Australia in 1995 as a Wellcome Senior Research Fellow at the University of Melbourne at the Bone Marrow Research Laboratories in the Royal Melbourne Hospital. In 2000, he became the Director of the laboratories, and then in 2005 he became a Principal Research Fellow of the National Health and Medical Research Council (NHMRC) and a Professor of Medicine at the University of Melbourne in 2006.

Presently, Professor Jane is Head of Department of Medicine, Monash University; Director of Research, Alfred Hospital; and Head of School, Central Clinical School, Melbourne, Australia. He has a range of research interests primarily investigating both developmental and acquired disorders of the blood and skin, which involves the study of gene transcription. He has published over 90 papers including articles in Science, Nature Medicine and Developmental Cell. Recently, he developed a drug, the patent of which was sold to Merck for over \$500 million.



### **Dr. Shuaiying Cui, Ph.D.**

Obtained his Ph.D. in genetics from the University of Science and Technology of China in 2006, after which he became a Post Doc in the Department of Hematology/Oncology at the University of Michigan. Following this, in 2010 he became a Post Doc in the Department of Cell and Developmental Biology at the same university and in 2012 he was became a Research Investigator in the Department of Cell and Developmental Biology. Currently he is an Assistant Professor at the Boston University School of Medicine, Department of Medicine, Hematology & Medical Oncology, working closely with Professor Martin H. Steinberg.

Dr. Cui's research is focused on the development of novel agents that can elicit developmental stage-specific gene silencing or reprogramming in hematopoietic stem cells and progenitors through a series of epigenetic chromatin modifications by nucleosome remodeling, histone deacetylation and demethylation. These agents can be applied to the treatment of the patients with hematologic disorders, such as sickle cell disease and beta-thalassemia, as well as acute myeloid leukemia (Blood cancer), which arise from congenital defects in genome. The findings from these preclinical studies could also help to establish therapeutic indications in other hematological malignancies. Dr. Cui has published over 17 papers including several articles in Blood and American Journal of Hematology.



### **Dr. Brian M. Mozeleski, Ph.D.**

Graduated from the University of Massachusetts in 2007 before joining the Pasteur Institute in Paris, France, where he obtained his PhD in immunology in 2014 (Top honors "tres honorable")

In 2014, he was appointed Entrepreneur in Residence at Harvard Medical School in Boston where he led the entrepreneurial development of MyoSyntax corporate concept and conceived novel multi-parametric flow cytometry panels correlating blood and tissue- resident immune cell function to physical function declines in HIV•infected and aging individuals. His other achievements include leading strategic business and entrepreneurial exploration of a novel muscle health diagnostic technology, leading licensing acquisition of anabolic profiling technology from Harvard Medical School .

Currently, he is the principal investigator leading ongoing research projects related to National Institutes of Health (NIH), Small Business for Innovative research, specifically related to profiling of sickle cell anemia severity and also algorithmic rank profiling of physical function and muscle modulation. Dr. Mozeleski has published seven papers including articles in Eukaryotic Cell and Journal of

Experimental Medicine and he also has seven patents.



### **Dr. Abdulrahman Al Sultan , MD**

Obtained his medical degree from King Saud University, Riyadh Saudi Arabia. He entered the pediatric training program at the University of Iowa Hospitals and Clinics and obtained the American Pediatric Board on 2004. Following this Dr AlSultan obtained his Postdoctoral Research Fellowship in 2008 at the University of Colorado Denver and National Jewish Research & Medical Ctr. He was appointed as Assistant Professor and Attending Physician, Hematology & Oncology section, Department of Pediatrics, College of medicine and King Khalid University Hospital, Riyadh, Saudi Arabia on November 2008.

Dr Al Sultan was promoted to the rank of Associate professor on November 2013. He has been appointed as Director of Pediatric Stem Cell Transplant Program, Department of Pediatric Hematology/Oncology, King Abdullah Specialist Children Hospital, Riyadh, Saudi Arabia on January 2014.

Dr. Al Sultan's research is focused on the sickle cell anemia. Leukemia and bone marrow stem cell transplantation. He has published over 40 papers including articles in New England Journal of Medicine, Blood and Stem Cell Reports.